Temozolomide plus bevacizumab well-tolerated in hemangiopericytomas and malignant solitary fibrous tumors
Park MS. Cancer. 2011;doi:10.1002/cncr.26098.
Click Here to Manage Email Alerts
Results from a small retrospective study of patients with hemangiopericytomas and malignant solitary fibrous tumors suggest that the combination of temozolomide and bevacizumab is well-tolerated and may provide clinical benefit.
Hemangiopericytomas and solitary fibrous tumors (HPC/SFT) are closely related soft tissue sarcomas that appear to exhibit fibroblastic-type differentiation and typically affect adults aged 20 to 70 years. These tumors can appear anywhere in the body, but are most commonly found in the lower extremities, retroperitoneum/pelvis, lung/pleura and meninges.
Researchers at The University of Texas MD Anderson Cancer Center reviewed the records of 14 patients treated for HPC/SFT from May 2005 to June 2007. All patients were assigned to 150 mg/m2 temozolomide (Temodar, Schering-Plough) and 5 mg/kg IV bevacizumab (Avastin, Genentech).
The objective response rate was 79% (95% CI, 49.2-95.3) at a median of 34 months’ follow-up. Researchers determined that all responding patients had Choi partial response. Two patients (14%) had Choi stable disease and one patient had progressive disease. Median time to response was 2.5 months.
One patient had a reduction in tumor size, three had reductions in tumor density and seven patients had both. Ten patients (71%) showed some degree of tumor shrinkage with a median decrease of 10.1%.
Ten patients demonstrated reduction in tumor density of at least a 15%. The median percent decrease in density was 26.2%.
All patients had discontinued therapy at the time of this analysis. Six patients discontinued for disease progression, two others developed thrombocytopenia and one patient discontinued due to fungal infection.
Follow HemOncToday.com on Twitter. |